Which has preferable earnings & valuation, PXMD or ARDS?

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Aridis Pharmaceuticals N/A N/A -$30.37M $0.09 N/A

Is PXMD or ARDS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Aridis Pharmaceuticals N/A N/A N/A

Which has stronger valuation & earnings, VRPX or PXMD?

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virpax Pharmaceuticals N/A N/A -$15.19M -$123.25 N/A PaxMedica N/A N/A -$18.29M -$6.09 N/A

Is VRPX or PXMD more profitable?

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% PaxMedica N/A -3,167.89% -560.35%

Is PXMD or NAVB more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Navidea Biopharmaceuticals N/A N/A N/A

Is GNCA or PXMD more profitable?

Genocea Biosciences' return on equity of -182.88% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A -182.88% -62.76% PaxMedica N/A -3,167.89% -560.35%

Which has preferable earnings & valuation, PXMD or GNCAQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PaxMedica N/A N/A -$18.29M -$6.09 N/A Genocea Biosciences N/A N/A N/A N/A N/A

Is PXMD or GNCAQ more profitable?

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Genocea Biosciences N/A N/A N/A

PaxMedica (PXMD) Competitors

$0.0005 0.00 (0.00%)

As of 07/2/2026

Compare

PXMD vs. ARDS, VRPX, NAVB, GNCA, and GNCAQ

Should you buy PaxMedica stock or one of its competitors? MarketBeat compares PaxMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PaxMedica include Aridis Pharmaceuticals (ARDS), Virpax Pharmaceuticals (VRPX), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry.

How does PaxMedica compare to Aridis Pharmaceuticals?

PaxMedica (NASDAQ:PXMD) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Aridis Pharmaceuticals	Neutral

PaxMedica is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.09	N/A

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, meaning that its share price is 4,397% more volatile than the broader market.

Aridis Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Aridis Pharmaceuticals	N/A	N/A	N/A

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats PaxMedica on 7 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
PaxMedica	Neutral

Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

Virpax Pharmaceuticals' return on equity of -1,554.34% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
PaxMedica	N/A	-3,167.89%	-560.35%

Virpax Pharmaceuticals has a beta of -16.52, indicating that its stock price is 1,752% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Virpax Pharmaceuticals beats PaxMedica on 5 of the 8 factors compared between the two stocks.

How does PaxMedica compare to Navidea Biopharmaceuticals?

PaxMedica (NASDAQ:PXMD) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Navidea Biopharmaceuticals has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Navidea Biopharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Navidea Biopharmaceuticals	N/A	N/A	N/A

4.9% of PaxMedica shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Navidea Biopharmaceuticals	Neutral

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Genocea Biosciences' return on equity of -182.88% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
PaxMedica	N/A	-3,167.89%	-560.35%

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 1.0% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PaxMedica has lower revenue, but higher earnings than Genocea Biosciences. PaxMedica is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
PaxMedica	Neutral

Summary

Genocea Biosciences beats PaxMedica on 6 of the 9 factors compared between the two stocks.

How does PaxMedica compare to Genocea Biosciences?

PaxMedica (NASDAQ:PXMD) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Genocea Biosciences	N/A	N/A	N/A

4.9% of PaxMedica shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Genocea Biosciences	Neutral

PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

Summary

Genocea Biosciences beats PaxMedica on 4 of the 6 factors compared between the two stocks.

Get PaxMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

PXMD vs. The Competition

Export

Metric	PaxMedica	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6K	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.00	1.66	28.02	24.70
Price / Sales	N/A	127.53	540.37	99.46
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.00	8.17	10.96	6.46
Net Income	-$18.29M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

PaxMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	2
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	N/A	$21K	N/A	0.00	30	Gap Down
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	-97.1%	$14K	N/A	N/A	7
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PXMD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PaxMedica (PXMD) Competitors

PXMD vs. ARDS, VRPX, NAVB, GNCA, and GNCAQ

How does PaxMedica compare to Aridis Pharmaceuticals?

Summary

How does PaxMedica compare to Virpax Pharmaceuticals?

Summary

How does PaxMedica compare to Navidea Biopharmaceuticals?

Summary

How does PaxMedica compare to Genocea Biosciences?

Summary

How does PaxMedica compare to Genocea Biosciences?

Summary

New MarketBeat Followers Over Time

PXMD vs. The Competition

PaxMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PaxMedica (PXMD) Competitors

PXMD vs. ARDS, VRPX, NAVB, GNCA, and GNCAQ

How does PaxMedica compare to Aridis Pharmaceuticals?

Does the media refer more to PXMD or ARDS?

Which has preferable earnings & valuation, PXMD or ARDS?

Which has more volatility & risk, PXMD or ARDS?

Is PXMD or ARDS more profitable?

Do institutionals and insiders hold more shares of PXMD or ARDS?

Summary

How does PaxMedica compare to Virpax Pharmaceuticals?

Does the media favor VRPX or PXMD?

Which has stronger valuation & earnings, VRPX or PXMD?

Is VRPX or PXMD more profitable?

Which has more risk and volatility, VRPX or PXMD?

Do institutionals and insiders hold more shares of VRPX or PXMD?

Summary

How does PaxMedica compare to Navidea Biopharmaceuticals?

Which has higher earnings and valuation, PXMD or NAVB?

Is PXMD or NAVB more profitable?

Do institutionals and insiders hold more shares of PXMD or NAVB?

Does the media prefer PXMD or NAVB?

Which has more volatility and risk, PXMD or NAVB?

Summary

How does PaxMedica compare to Genocea Biosciences?

Is GNCA or PXMD more profitable?

Do institutionals & insiders believe in GNCA or PXMD?

Which has better valuation & earnings, GNCA or PXMD?

Which has more risk & volatility, GNCA or PXMD?

Does the media favor GNCA or PXMD?

Summary

How does PaxMedica compare to Genocea Biosciences?

Which has preferable earnings & valuation, PXMD or GNCAQ?

Is PXMD or GNCAQ more profitable?

Do institutionals & insiders believe in PXMD or GNCAQ?

Does the media prefer PXMD or GNCAQ?

Which has more risk & volatility, PXMD or GNCAQ?

Summary

New MarketBeat Followers Over Time

PXMD vs. The Competition

PaxMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools